Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | HTR6 | P50406 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.42 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.42 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA3 | P07451 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4993025 | 0.84 | GRM4 (0.51) | MEN1KMT2AMAPTALDH1A1LMNA | |
| SCHEMBL1940137 | 0.83 | ALDH1A1 (0.42) | MEN1KMT2AMAPTALDH1A1LMNA | |
| SCHEMBL29493429 | 0.80 | GAA (0.53) | MEN1KMT2AMAPTALDH1A1LMNA | |
| SCHEMBL27463601 | 0.80 | GRM4 (0.51) | MEN1KMT2AMAPTALDH1A1LMNA | |
| SCHEMBL2574273 | 0.80 | GRM4 (0.48) | MEN1KMT2AMAPTALDH1A1LMNA | |
| SCHEMBL422433 | 0.80 | GRM4 (0.48) | MEN1KMT2AMAPTALDH1A1LMNA | |
| SCHEMBL3439397 | 0.78 | GRM4 (0.46) | MEN1KMT2AMAPTALDH1A1LMNA | |
| SCHEMBL3439395 | 0.78 | GRM4 (0.46) | MEN1KMT2AMAPTALDH1A1LMNA | |
| SCHEMBL568158 | 0.78 | GRM4 (0.46) | MEN1KMT2AMAPTALDH1A1LMNA | |
| SCHEMBL2578089 | 0.76 | MAPT (0.57) | MEN1KMT2AMAPTALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116283910-A | Benzimidazole compounds as C-KIT inhibitors | 阿瑞雅德制药公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-116178343-A | Benzimidazole compounds as C-KIT inhibitors | 阿瑞雅德制药公司 | 2023-05-30 | — | — | CN | disclosed |
| CN-110291081-B | Benzimidazole compounds as C-KIT inhibitors | 阿瑞雅德制药公司 | 2023-01-31 | — | — | CN | disclosed |
| US-20220064144-A1 | BENZIMIDAZOLE COMPOUNDS AS C-KIT INHIBITORS | ARIAD PHARMACEUTICALS, INC. | 2022-03-03 | — | — | US | disclosed |
| US-11197867-B2 | Aminopyrimidinyl compounds | PFIZER INC. (US) | 2021-12-14 | — | — | US | disclosed |
| US-20210377495-A1 | AMINOPYRIMIDINYL COMPOUNDS | PFIZER INC. (US) | 2021-12-02 | — | — | US | disclosed |
| US-11117883-B2 | Benzimidazole compounds as c-Kit inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2021-09-14 | — | — | US | disclosed |
| US-10980815-B2 | Aminopyrimidinyl compounds | PFIZER INC. (US) | 2021-04-20 | — | — | US | disclosed |
| US-20200330477-A1 | AMINOPYRIMIDINYL COMPOUNDS | PFIZER INC. (US) | 2020-10-22 | — | — | US | disclosed |
| US-20200039958-A1 | BENZIMIDAZOLE COMPOUNDS AS C-KIT INHIBITORS | ARIAD PHARMACEUTICALS, INC. | 2020-02-06 | — | — | US | disclosed |
| US-7939671-B2 | Compounds that inhibit (block) bitter taste in composition and use thereof | SENOMYX, INC. (US) | 2011-05-10 | — | — | US | disclosed |
| US-7939671-B2 | Compounds that inhibit (block) bitter taste in composition and use thereof | SENOMYX, INC. (US) | 2011-05-10 | — | — | US | disclosed |
| US-20100254916-A1 | Identification of human T2R receptors that respond to bitter compounds that elicit the bitter taste in compositions, and the use thereof in assays to identify compounds that inhibit (block) bitter taste in compositions and use thereof | SENOMYX, INC. (US) | 2010-10-07 | — | — | US | disclosed |
| US-20100254916-A1 | Identification of human T2R receptors that respond to bitter compounds that elicit the bitter taste in compositions, and the use thereof in assays to identify compounds that inhibit (block) bitter taste in compositions and use thereof | SENOMYX, INC. (US) | 2010-10-07 | — | — | US | disclosed |
| US-20100254916-A1 | Identification of human T2R receptors that respond to bitter compounds that elicit the bitter taste in compositions, and the use thereof in assays to identify compounds that inhibit (block) bitter taste in compositions and use thereof | SENOMYX, INC. (US) | 2010-10-07 | — | — | US | disclosed |
| EP-2195656-A2 | HUMAN T2R BITTERNESS RECEPTORS AND USES THEREOF | Senomyx, Inc. (US) | 2010-06-16 | — | — | EP | disclosed |
| US-20090274632-A1 | Identification of human T2R receptors that respond to bitter compounds that elicit the bitter taste in compositions, and the use thereof in assays to identify compounds that inhibit (block) bitter taste in composition and use thereof | SENOMYX, INC. (US) | 2009-11-05 | — | — | US | disclosed |
| US-20090274632-A1 | Identification of human T2R receptors that respond to bitter compounds that elicit the bitter taste in compositions, and the use thereof in assays to identify compounds that inhibit (block) bitter taste in composition and use thereof | SENOMYX, INC. (US) | 2009-11-05 | — | — | US | disclosed |
| US-20090274632-A1 | Identification of human T2R receptors that respond to bitter compounds that elicit the bitter taste in compositions, and the use thereof in assays to identify compounds that inhibit (block) bitter taste in composition and use thereof | SENOMYX, INC. (US) | 2009-11-05 | — | — | US | disclosed |
| WO-2009025793-A2 | HUMAN T2R BITTERNESS RECEPTORS AND USES THEREOF | SENOMYX, INC. (US) | 2009-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090274632-A1 | Identification of human T2R receptors that respond to bitter compounds that elicit the bitter taste in compositions, and the use thereof in assays to identify compounds that inhibit (block) bitter taste in composition and use thereof | TAS2R50, TAS2R1, TAS2R30 | MEN1 2114/4885KMT2A 3206/4885MAPT 3488/4885 |
| US-20200039958-A1 | BENZIMIDAZOLE COMPOUNDS AS C-KIT INHIBITORS | KIT, TNNI3K, CDKN1A | MEN1 1092/4885KMT2A 321/4885MAPT 3346/4885 |
| US-20100254916-A1 | Identification of human T2R receptors that respond to bitter compounds that elicit the bitter taste in compositions, and the use thereof in assays to identify compounds that inhibit (block) bitter taste in compositions and use thereof | TAS2R50, TAS2R1, TAS2R30 | MEN1 2097/4885KMT2A 3181/4885MAPT 3501/4885 |
| US-11197867-B2 | Aminopyrimidinyl compounds | CNKSR1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SSTR3 | MEN1 1024/4885KMT2A 2615/4885MAPT 4732/4885 |
| US-20220064144-A1 | BENZIMIDAZOLE COMPOUNDS AS C-KIT INHIBITORS | KIT, TNNI3K, CDKN1A | MEN1 1092/4885KMT2A 321/4885MAPT 3346/4885 |
| US-10980815-B2 | Aminopyrimidinyl compounds | JAK2, JAK1, JAK3 | MEN1 1581/4885KMT2A 122/4885MAPT 3076/4885 |
| US-11117883-B2 | Benzimidazole compounds as c-Kit inhibitors | KIT, TNNI3K, CDKN1A | MEN1 1092/4885KMT2A 321/4885MAPT 3346/4885 |
| US-20200330477-A1 | AMINOPYRIMIDINYL COMPOUNDS | CNKSR1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SSTR3 | MEN1 1024/4885KMT2A 2615/4885MAPT 4732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.